$CLOV

Wai Conrad sold $113K of CLOV

Wai Conrad (CEO, Counterpart Health) sold 24,215 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 ($0.11M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wai Conrad
Published Jul 16, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on CEO selling activity (shares, price, and post-transaction holdings) but does not introduce new operational or financial information.

02

Market read

Useful for monitoring insider behavior, but unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

Traders may over-weight insider sales; the filing does not disclose changes to guidance, contracts, or regulatory/clinical developments.

Relevance 3/10Novelty 3/10Timing: new Form 4 filed 2026-07-16, covering a sale dated 2026-07-15

Background

The article is a SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. /DE.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health CEO Wai Conrad sold 24,215 shares at $4.6700 on 2026-07-15 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, with any impact confined to short-term sentiment rather than fundamentals.

Evidence & confidence

The filing is a routine Form 4 transaction with disclosed trade size, price, and 10b5-1 pre-arrangement, providing no new company-specific operating or financial information.

Market effects

Minimal, as this is company-specific insider selling with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • CLOV

    Clover Health Investments, Corp. /DE, the company whose CEO insider sale is disclosed.

  • Wai Conrad

    CEO, Counterpart Health, who sold 24,215 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$CLOVHigh

Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.

$CLOVMed

Clover Health (CLOV) Shares Skyrocket, What You Need To Know

Clover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$CLOVHighAI 8/10

Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes

Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.